Provided by Tiger Trade Technology Pte. Ltd.

Seres Therapeutics

4.96
+0.05001.02%
Volume:8K
Turnover:41.54K
Market Cap:49.82M
PE:-2.05
High:5.10
Open:4.99
Low:4.96
Close:4.91
52wk High:29.98
52wk Low:4.32
Shares:10.04M
Float Shares:8.83M
Volume Ratio:1.71
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4137
EPS(LYR):0.6400
ROE:-66.57%
ROA:-39.85%
PB:1.44
PE(LYR):7.75

Loading ...

Seres Therapeutics Q1 EPS $(2.08) Misses $(1.88) Estimate, Sales $358.000K

Benzinga Earnings
·
May 05

Seres Q1 FY26 net loss turns to USD 19.9 million; revenue at USD 358,000

Reuters
·
May 05

BRIEF-Seres Therapeutics Q1 EPS USD -2.08

Reuters
·
May 05

Seres Therapeutics Inc: as of March 31, 2026, Seres Had $29.8 Mln in Cash and Cash Equivalents,Expects to Fund Operations Through Q3 of 2026

THOMSON REUTERS
·
May 05

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

GlobeNewswire
·
May 04

Seres Therapeutics Inc expected to post a loss of $1.88 a share - Earnings Preview

Reuters
·
May 01

Seres Therapeutics announces three presentations at 2026 ESCMID congress

TIPRANKS
·
Apr 20

Seres says Phase 1b trial shows SER-155 shifts gut microbiome in allo-HCT patients

Reuters
·
Apr 20

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

GlobeNewswire
·
Apr 20

Seres Therapeutics presents at CARB-X Investor Day, highlights SER-428 development

Reuters
·
Apr 09

Seres Therapeutics Sets 2026 Annual Shareholder Meeting Date

TIPRANKS
·
Mar 17

Seres Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Mar 14

Canaccord Genuity Remains a Buy on Seres Therapeutics (MCRB)

TIPRANKS
·
Mar 13

Seres Therapeutics reports FY25 EPS 64c

TIPRANKS
·
Mar 12

Seres Therapeutics Q4 EPS $(1.76) Beats $(2.22) Estimate, Sales $438.000K Miss $5.875M Estimate

Benzinga Earnings
·
Mar 12

Seres Therapeutics FY2025 net income from continuing operations was USD 5.7 million

Reuters
·
Mar 12

BRIEF-Seres Therapeutics FY EPS USD 0.64

Reuters
·
Mar 12

Seres Therapeutics FY Collaboration Revenue USD 789 Thousand

THOMSON REUTERS
·
Mar 12

Seres Therapeutics FY Operating Income USD -93.971 Million

THOMSON REUTERS
·
Mar 12

Seres Therapeutics FY Net Income USD 5.696 Million

THOMSON REUTERS
·
Mar 12